The quiet revolution in how we take our medicine

The quiet revolution in how we take our medicine

Ravi Kumar, Global Head of Injectables & Corporate Strategy, Portfolio and SPO

Published on Money Control, 05 Jun 2026

Three out of four new biologic approvals are now device-based pens, prefilled syringes, autoinjectors, and increasingly wearable patches

Insulin made self-injection routine for the sick. GLP-1s have made it routine for everyone else. The next wave biologics for cancer, autoimmune disease, and chronic conditions is following them out of the hospital.

The pen on the kitchen counter does not look like a revolution. It is the colour of a children’s toy, smaller than a marker, and once a week someone clicks it against the skin of their thigh and the dose is delivered before the kettle boils.

Insulin pens have looked roughly like this since the 1980s, and people with diabetes have been quietly self-injecting at home for almost a century. What is new is who else is doing it.

In the four years since GLP-1 medicines entered mainstream conversation, the home-injection pen has detached from the cultural label of chronic illness. That shift, from “this is for people who are sick” to “this is just how some medicines come now,” is the most consequential thing GLP-1s have done. And it is dragging the rest of biologics out of the hospital behind them.

The shift is already mostly done

In 2000, only one in four newly approved biologic medicines came with a delivery device. The default was a vial in a pharmacy, an infusion suite, a nurse, and a chair. By 2023, that ratio had inverted. Three out of four new biologic approvals are now device-based pens, prefilled syringes, autoinjectors, and increasingly wearable patches.

A systematic review of every biologic-device combination cleared by the U.S. FDA over two decades captures the scale of the shift in a single line: 25 percent in 2000–04, 74 percent in 2023–25.

The market is following. Subcutaneous biologics were a $1.9 billion segment in 2024 and are projected to reach $5.4 billion by 2034. The autoinjector market is growing at roughly 14 percent a year. Device manufacturers have committed more than $500 million in new factory capacity since the start of 2024 alone.

Patients are unambiguous. Across published studies that compared subcutaneous and intravenous versions of the same drug, between 76-and-89 percent of patients preferred to inject themselves at home. A 2024 review of 61 separate clinical and economic outcomes found that 77 percent favoured home injection; only 3 percent favoured the hospital infusion.

What that means for hospitals and budgets

The most consequential effects will be in oncology. A patient on intravenous biologics for lymphoma, or for breast cancer, spends roughly 72 hours a year in an infusion chair, not counting travel and recovery. The same therapeutic effect, delivered subcutaneously, takes minutes.

The hospital math is starker. A fifty-patient infusion centre converting its patients to subcutaneous frees between 105 and 233 chair-days per year roughly an entire additional infusion suite, without building anything. Administering a biologic intravenously costs payors 50-to-66 percent more than giving it subcutaneously, and Spain has documented €3,000 to €3,700 per patient per year in savings on a Biologic purely from moving administration out of the clinic. Across a chronic-disease population, those numbers stop being line items and start being budgets.

Why this is happening now

For 30 years, the obstacle to home administration of large biologics was not patient preference. It was chemistry.

Most biologics are large molecules antibodies, fusion proteins, peptides that have to be delivered at high doses to do their job. Fitting a high dose into a small injection volume requires concentrating the protein up to 25 times above what an IV bag holds. At those concentrations, proteins tend to clump, thicken, and degrade. For decades, the resulting solutions were either too viscous to push through a needle or too unstable to sit in a pen for six months.

What changed is the formulation science. Several engineered excipient platforms from Halozyme’s hyaluronidase technology used in subcutaneous trastuzumab and rituximab, to a newer generation of high-concentration aqueous platforms now in commercial use have shown it is possible to hold proteins at 250 mg/mL while keeping the solution syringeable. On trastuzumab, native viscosity at 250 mg/mL is around 170 centipoise unsyringeable; engineered formulations bring it under 20 centipoises, the consistency of warm honey. The rate-limiting step is no longer whether the chemistry works, but who has the manufacturing capability to make it at the scale a global launch requires.

The supply chain is moving too

Building a high-concentration biologic and assembling it into a self-injection device is not something most pharmaceutical companies do in-house. The work spans live cell culture, protein purification, sterile fill-finish, and combination-product device assembly and it is increasingly the role of contract development and manufacturing organisations (CDMOs) to provide it under a single integrated quality system. The most consequential players in this transition are the smaller set of fully integrated CDMOs that can take a programme from cell line through to a finished autoinjector without handing it off between sites. A meaningful share of that integrated capacity now sits in India, which has built the regulatory infrastructure, the trained workforce, and the cost base to manufacture at global standards while preserving the margins that make subcutaneous biosimilars commercially viable. These companies are the back end of the home-injection shift, not its consumer face but without them, the pen on the kitchen counter does not get there.

The home is becoming the new clinic

What insulin did over the last century, and what GLP-1s have accelerated in the last four years, is to make self-injection unremarkable. Once a culture stops associating biological complexity with hospital infrastructure, it becomes very difficult to rebuild that association for any other disease.

The next decade will see the same migration play out across oncology, autoimmune disease, dermatology, and ophthalmology. Hospitals will not empty out; they will stop being the bottleneck for chronic biological therapy. Infusion suites will return to acute and complex cases. Patients will spend evenings on their sofas instead of mornings in waiting rooms. Health systems under capacity strain will get a small but real piece of their day back.

The pen on the kitchen counter is the most underrated medical innovation of the decade. It does not look like a revolution. That is the point.